Foshan Ionova Biotherapeutics Co. Ltd. has described proteolysis targeting chimeras (PROTACs) comprising an E3 ubiquitin-protein ligase binding moiety covalently linked to an androgen receptor variant 7 (AR-v7) targeting moiety acting as AR-v7 degradation inducers reported to be useful for the treatment of prostate cancer.